Published in Prostate on May 01, 2006
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer (2009) 1.15
Endometrial cysteine-rich secretory protein 3 is inhibited by human chorionic gonadotrophin, and is increased in the decidua of tubal ectopic pregnancy. Mol Hum Reprod (2009) 1.06
Cysteine-rich secretory protein 4 is an inhibitor of transient receptor potential M8 with a role in establishing sperm function. Proc Natl Acad Sci U S A (2011) 1.01
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
The role of cysteine-rich secretory proteins in male fertility. Asian J Androl (2010) 0.90
Identification of androgen-regulated genes in human prostate. Mol Med Rep (2012) 0.87
The present and future of prostate cancer urine biomarkers. Int J Mol Sci (2013) 0.85
Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. J Hematol Oncol (2014) 0.85
Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3. Asian J Androl (2010) 0.85
Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific. Asian J Androl (2010) 0.83
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues. Biomed Res Int (2013) 0.81
Copy number changes of CRISP3 in oral squamous cell carcinoma. Oncol Lett (2011) 0.80
Variation in PTCHD2, CRISP3, NAP1L4, FSCB, and AP3B2 associated with spherical equivalent. Mol Vis (2016) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica (2006) 1.64
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer (2004) 1.63
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 1.54
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol (2003) 1.49
A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J (2002) 1.47
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer (2010) 1.32
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol (2005) 1.28
Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood (2006) 1.27
Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem (2012) 1.26
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood (2002) 1.22
Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma (2006) 1.21
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril (2010) 1.15
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica (2011) 1.15
Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem (2004) 1.15
The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun (2005) 1.14
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics. Anal Chem (2009) 1.13
Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev (2010) 1.12
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev (2010) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma. Biochemistry (2004) 1.10
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol (2010) 1.09